Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
donepezil + idalopirdine
- Development stage
- Discontinued
- Lead developer
- Lundbeck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This drug is a fixed-dose combination of two small molecule agents, donepezil and idalopirdine, developed for the treatment of mild to moderate Alzheimer's disease. Donepezil is a selective, reversible acetylcholinesterase inhibitor that increases acetylcholine levels in the brain, thereby enhancing cholinergic neurotransmission and improving cognitive symptoms in Alzheimer's disease. Idalopirdine is a selective 5-hydroxytryptamine 6 (5-HT6) receptor antagonist; it modulates neurotransmitter systems involved in cognition by blocking 5-HT6 receptors expressed on glutamatergic neurons and GABAergic interneurons. The rationale for combining these drugs was to potentiate the effects of acetylcholinesterase inhibition with additional modulation of serotonergic pathways to further improve cognitive function. Clinical trials showed that while this combination was generally safe and well tolerated, it did not demonstrate significant efficacy over standard therapy[1][2][3][5].
- Brand names
- donepezil + idalopirdine
- Other names
- donepezil and idalopirdinecombination of donepezil and idalopirdine
02
Targets
HTR6 (5-hydroxytryptamine receptor 6)Acetylcholinesterase
Beyond the preview
Go deeper on donepezil + idalopirdine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on donepezil + idalopirdine.